Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2
Chun-ling Dai(Sun Yat-sen University), Liwu Fu(Sun Yat-sen University), Zhe‐Sheng Chen(New York College of Traditional Chinese Medicine), Si-Rong Wang(St. John's University), Robert W. Robey(National Institutes of Health), Xiao‐Dong Su(Peking University), Charles R. Ashby(St. John's University), Suresh V. Ambudkar(National Institutes of Health), Yan Huang(Chinese PLA General Hospital), Liming Chen(Université Claude Bernard Lyon 1), Cheng-Jun Shi(Sun Yat-sen University), Yong‐ju Liang(Sun Yat-sen University), Chung‐Pu Wu(Chang Gung University), Dong-geng Liu(Sun Yat-sen University), Amit K. Tiwari(University of Arkansas for Medical Sciences)
Cited by 385
Related Papers
Microbiota in health and diseases
|Signal Transduction and Targeted Therapy|2022|2.9k
KRAS mutation: from undruggable to druggable in cancer
|Signal Transduction and Targeted Therapy|2021|1k